Kosmider Suzanne, Lipton Lara
Department of Medical Oncology and Clinical Haematology, Western Hospital, Footscray 3011, Victoria, Australia.
World J Gastroenterol. 2007 Jul 28;13(28):3799-805. doi: 10.3748/wjg.v13.i28.3799.
The management of colon and rectal cancer has changed dramatically over the last 25 years. The use of adjuvant therapies has become standard practice in locally advanced (stage III and selected stage II) colorectal cancer. Improved surgical techniques, chemotherapeutics and radiotherapy are resulting in higher cure rates and the development of agents targeting proliferative and angiogenic pathways offer further promise. Here we explore risk factors for local and distant recurrence after resection of colon and rectal cancer, and the role of adjuvant treatments. Discussion will focus on the evidence base for adjuvant therapies utilised in colorectal cancer, and the treatment of sub-groups such as the elderly and stage II disease. The role of adjuvant radiotherapy in rectal cancer in reduction of recurrence will be explored and the role and optimal methods for surveillance post-curative resection with or without adjuvant therapy will also be addressed.
在过去25年里,结肠癌和直肠癌的治疗发生了巨大变化。辅助治疗的应用已成为局部晚期(III期和部分II期)结直肠癌的标准治疗方法。手术技术、化疗药物和放疗的改进使治愈率提高,针对增殖和血管生成途径的药物研发也带来了更多希望。在此,我们探讨结肠癌和直肠癌切除术后局部和远处复发的危险因素以及辅助治疗的作用。讨论将聚焦于结直肠癌辅助治疗的循证依据,以及老年患者和II期疾病等亚组的治疗。将探讨辅助放疗在直肠癌降低复发方面的作用,还将讨论根治性切除术后无论有无辅助治疗的监测作用及最佳方法。